Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume control Clear all
Completed Phase 4 Interventional

Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery

NCT04180943
View directory record Official record
Conditions
Anesthesia, Local
Interventions
interscalene nerve block
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional Results available

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

NCT00215540
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions
Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
3 Days to 10 Days
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 4 Interventional Results available

Intercostal Nerve Cryoablation for Postoperative Pain Management

NCT03972397
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intercostal Nerve Cryoablation, Bupivacaine liposomal injectable suspension, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

NCT04524949
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IMCY-0098 450 μg, IMCY-0098 1350 μg, Placebo
Drug
Lead sponsor
Imcyse SA
Industry
Eligibility
18 Years to 44 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

NCT04521738
View directory record Official record
Conditions
Overweight, Healthy Subjects
Interventions
SAR441255, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

High Volume Lactated Ringer's Solution and Pancreatitis

NCT02050048
View directory record Official record
Conditions
Pancreatitis
Interventions
Administration of Lactated Ringer's (LR) Solution
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Evanston, Illinois • Highland Park, Illinois • Skokie, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Periodontal Phenotype Study (Tooth Extraction)

NCT02668289
View directory record Official record
Conditions
Tooth Extraction Status Nos
Interventions
consent, Screening, Xray, PVS Impressions, Photographs, CBCT, Anesthesia, Extraction, Clinical measurements
Other · Procedure
Lead sponsor
Gustavo Avila-Ortiz DDS, MS, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 29, 2026, 11:53 PM EDT
Not yet recruiting Not applicable Interventional

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110
View directory record Official record
Conditions
Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions
Ultrafiltration
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT03571334
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

NCT03647917
View directory record Official record
Conditions
Skin Aging of Face and Hands
Interventions
Platelet Rich Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 29, 2026, 11:53 PM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01521923
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

NCT04968990
View directory record Official record
Conditions
Wilms Tumor
Interventions
Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection, Surgical Resection, Partial Nephrectomy
Device · Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Epidural Blood Patch on the Resolution of Postdural Puncture Headache (PDPH)

NCT00373074
View directory record Official record
Conditions
Post-Lumbar Puncture Headache
Interventions
Epidural Blood Patch
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional Results available

Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia

NCT00928564
View directory record Official record
Conditions
Pelvic Floor Muscle Spasm
Interventions
Pudendal block, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy

NCT03230032
View directory record Official record
Conditions
Infant Development, Infant,Premature, Hydrocephalus, Neonatal Encephalopathy, Infarction, PVL, Thrombosis, Intraventricular Hemorrhage
Interventions
pacifier-activated device
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
32 Weeks to 12 Months
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 29, 2026, 11:53 PM EDT
Terminated Not applicable Interventional Results available

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

NCT00329732
View directory record Official record
Conditions
Migraine
Interventions
0.5% bupivicaine and 2% lidocaine, Saline placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

NCT04998201
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-APOC3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Breathing Perception in Respiratory Control

NCT07470099
View directory record Official record
Conditions
Work of Breathing
Interventions
Ambient Noise, Increased Auditory Feedback, Noise Distraction
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

NCT01566877
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-7288, Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 29, 2026, 11:53 PM EDT
Recruiting Phase 2 Interventional

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

NCT04153422
View directory record Official record
Conditions
Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
Interventions
Panzyga IVIG, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 29, 2026, 11:53 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Planning Actions for Consistent Engagement

NCT07447401
View directory record Official record
Conditions
Physical Activity, Cognition, Habits
Interventions
Non-PA Action Planning, PA Action Planning, Consistency in Action Plans
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
60 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 29, 2026, 11:53 PM EDT